陳俊翰 副教授
(Chun-Han Chen, Ph.D)

電話 | Tel02-27361661#3195
電子郵件 | E-mailbrianchc@tmu.edu.tw
最高學歷 | Education台大醫學院 藥理學博士
研究專長 | Research Interests分子藥理學、抗癌新藥研發、表觀遺傳學
經歷 | Experience台北醫學大學癌症生物學與藥物研發博士學位學程博士後研究員2014/3~2016/3
中央研究院基因體研究中心博士後研究員2013/7~2014/3
台灣大學藥理所博士後研究員2012/2~2013/7
美國俄亥俄州立大學藥學院訪問學者2008/9~2010/8
研究計畫 | Research Projects
  • 針對Class III PI3K為標靶所設計之抗癌新藥開發與機轉探討(2016/08/01~2017/07/31)
代表著作 | Research Paper
  • Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment . Cancers. 2021 Dec 4;13(23):6117. (Corresponding author).
  • Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas. Cancers. 2020 Dec 1;12(12):E3597. (First author)
  • MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells. Cancers. 2019 Oct 22;11(10). (Corresponding author).
  • Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells. Cancers. 2019 Sep 11;11(9). (First author)
  • Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer. Clin Cancer Res. 2018 Mar 1;24(5):1176-1189. (First author)